These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35013934)

  • 1. Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.
    Heilman KM; Nadeau SE
    Neurotherapeutics; 2022 Jan; 19(1):99-116. PubMed ID: 35013934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
    N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
    Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):289-303. PubMed ID: 38822731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives.
    Sultzer DL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):78-90. PubMed ID: 14566100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
    Mintzer JE
    J Clin Psychiatry; 2001; 62 Suppl 21():23-5. PubMed ID: 11584984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
    J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.